Edition:
United Kingdom

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

125.59USD
15 Dec 2017
Change (% chg)

$1.93 (+1.56%)
Prev Close
$123.66
Open
$130.16
Day's High
$131.76
Day's Low
$123.90
Volume
1,693,735
Avg. Vol
505,613
52-wk High
$147.63
52-wk Low
$35.98

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $11,251.10
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-FDA Lifts Clinical Hold On Fitusiran

* ALNYLAM PHARMACEUTICALS INC - CLINICAL TRIAL DOSING TO RESUME AROUND YEAR-END 2017

15 Dec 2017

FDA allows Alnylam to restart hemophilia treatment trials

The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

15 Dec 2017

UPDATE 1-FDA allows Alnylam to restart hemophilia treatment trials

Dec 15 The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

15 Dec 2017

FDA allows Alnylam to restart hemophilia treatment trials

Dec 15 The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical tests on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

15 Dec 2017

BRIEF-Alnylam Completes NDA Submission To U.S. FDA For Patisiran For Treatment Of HATTR Amyloidosis

* ALNYLAM COMPLETES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-T. Rowe Price Associates Reports 11.7 Pct Passive Stake In Alnylam Pharmaceuticals

* T. ROWE PRICE ASSOCIATES INC REPORTS 11.7 PERCENT PASSIVE STAKE IN ALNYLAM PHARMACEUTICALS INC AS OF NOVEMBER 30 - SEC FILING Source text : http://bit.ly/2ALIqHV Further company coverage:

11 Dec 2017

BRIEF-FDA grants Alnylam breakthrough therapy designation for Patisiran

* U.S. Food and Drug Administration (FDA) grants Alnylam breakthrough therapy designation (BTD) for Patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis with polyneuropathy

20 Nov 2017

BRIEF-Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran

* Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran

16 Nov 2017

BRIEF-Alnylam initiates rolling submission of NDA to U.S. FDA for HATTR amyloidosis treatment

* Alnylam initiates rolling submission of new drug application (NDA) to U.S. Food and drug administration (FDA) for patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis

16 Nov 2017

BRIEF-EMA grants Alnylam accelerated assessment of rare disease drug

* European Medicines Agency (EMA) grants Alnylam accelerated assessment of patisiran for patients with hereditary attr (hattr) amyloidosis

13 Nov 2017

Earnings vs. Estimates